Get the Stockscreener App
67.17
0.78%
-0.525
After Hours:
67.18
0.005
+0.01%
Cg Oncology Inc stock is traded at $67.17, with a volume of 743.65K.
It is down -0.78% in the last 24 hours and down -0.45% over the past month.
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
See More
Previous Close:
$67.70
Open:
$68.64
24h Volume:
743.65K
Relative Volume:
0.64
Market Cap:
$5.91B
Revenue:
$4.04M
Net Income/Loss:
$-161.00M
P/E Ratio:
-32.26
EPS:
-2.0823
Net Cash Flow:
$-132.48M
1W Performance:
+2.48%
1M Performance:
-0.45%
6M Performance:
+76.96%
1Y Performance:
+138.38%
1-Day Range:
$66.42
$69.69
1-Week Range:
$63.84
$69.69
52-Week Range:
$21.00
$73.56
Cg Oncology Inc Stock (CGON) Company Profile
Name
Cg Oncology Inc
Sector
Industry
Phone
(949) 419-6203
Address
400 SPECTRUM CENTER DRIVE, IRVINE
Compare CGON vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CGON
Cg Oncology Inc
|
67.17 | 5.96B | 4.04M | -161.00M | -132.48M | -2.0823 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Cg Oncology Inc Stock (CGON) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-11-25 | Initiated | Wedbush | Outperform |
| Nov-24-25 | Initiated | Truist | Buy |
| Oct-08-25 | Initiated | Guggenheim | Buy |
| Aug-19-25 | Initiated | Piper Sandler | Overweight |
| Jul-10-25 | Resumed | Goldman | Buy |
| May-02-25 | Initiated | JP Morgan | Overweight |
| Apr-16-25 | Initiated | Scotiabank | Sector Perform |
| Jan-07-25 | Initiated | TD Cowen | Buy |
| Oct-24-24 | Initiated | UBS | Buy |
| Sep-23-24 | Initiated | RBC Capital Mkts | Outperform |
| Aug-28-24 | Initiated | ROTH MKM | Buy |
| Jun-28-24 | Initiated | BofA Securities | Buy |
| Feb-20-24 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-20-24 | Initiated | Goldman | Neutral |
| Feb-20-24 | Initiated | Morgan Stanley | Overweight |
| Feb-14-24 | Initiated | H.C. Wainwright | Buy |
View All
Cg Oncology Inc Stock (CGON) Latest News
CG Oncology, Inc. (CGON) upgraded to buy: Here's what you should know - MSN
Wall Street Analysts Think CG Oncology, Inc. (CGON) Could Surge 29.78%: Read This Before Placing a Bet - Zacks Investment Research
CEO Arthur Kuan to speak at Bank of America, RBC health events - Stock Titan
CG Oncology to Present at Upcoming Investor Conferences in May - The Manila Times
Are Medical Stocks Lagging Brainsway (BWAY) This Year? - Yahoo Finance
UBS Group AG Cuts Stake in CG Oncology, Inc. $CGON - MarketBeat
Could Rising Earnings Estimates and a Zacks Upgrade Redefine CG Oncology’s Core Story (CGON)? - simplywall.st
CG Oncology, Inc. $CGON Shares Purchased by Universal Beteiligungs und Servicegesellschaft mbH - MarketBeat
282,506 Shares in CG Oncology, Inc. $CGON Acquired by Jennison Associates LLC - MarketBeat
CG Oncology, Inc. (CGON) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Why CG Oncology Shares Are Suddenly Sliding Now - TipRanks
H.C. Wainwright Maintains CG Oncology(CGON.US) With Buy Rating, Maintains Target Price $100 - Moomoo
CG Oncology (CGON) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Pictet Asset Management Holding SA Has $56.03 Million Position in CG Oncology, Inc. $CGON - MarketBeat
Why CG Oncology, Inc. Shares Are Sliding Today - TipRanks
UBS reiterates CG Oncology stock Buy rating on trial data By Investing.com - Investing.com Canada
CG Oncology Pivot-006 Data in Early June Seen as 'Complex' Catalyst, RBC Says - marketscreener.com
RBC Raises Price Target on CG Oncology to $79 From $73, Keeps Outperform, Speculative Risk - marketscreener.com
RBC Capital raises CG Oncology stock price target to $79 on trial outlook By Investing.com - Investing.com South Africa
RBC Capital raises CG Oncology stock price target to $79 on trial outlook - Investing.com Nigeria
CG Oncology (NASDAQ:CGON) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat
CG Oncology (NASDAQ: CGON) 2026 proxy details board, pay and auditor votes - Stock Titan
CGON Forecast, Price Target & Analyst Ratings | CG ONCOLOGY INC (NASDAQ:CGON) - ChartMill
Is CG Oncology’s New CFO Hire (CGON) Reframing Its Oncolytic Immunotherapy Investment Story? - Yahoo Finance
CG Oncology, Inc. urges break in recurrence cycle for bladder cancer patients - Traders Union
Analysts Offer Insights on Healthcare Companies: Monopar Therapeutics Inc (MNPR), ClearPoint Neuro (CLPT) and CG Oncology, Inc. (CGON) - The Globe and Mail
CG Oncology (CGON) Is Up 6.8% After Naming Biotech Veteran Jim DeTore CFOHas The Bull Case Changed? - simplywall.st
CG Oncology (CGON) Rallied on Pivotal Clinical Results - Insider Monkey
CGON SEC FilingsCG Oncology, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
CG Oncology (NASDAQ:CGON) Director Sells $1,138,956.00 in Stock - MarketBeat
CG Oncology Insider Sold Shares Worth $1,138,956, According to a Recent SEC Filing - Moomoo
Cg oncology director James Mulay reduces stake by $1.14m - Investing.com
CG Oncology (CGON) director exits 15,600-share position via 10b5-1 sale - Stock Titan
CG Oncology, Inc. (NASDAQ:CGON) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
CG Oncology (NASDAQ:CGON) Reaches New 52-Week High After Analyst Upgrade - MarketBeat
CG Oncology stock reaches all-time high at 72.0 USD By Investing.com - Investing.com Australia
CGON Maintained by JP Morgan -- Price Target Raised to $91.00 - GuruFocus
CGON Stock Climbs As Analysts Boost Price Targets - timothysykes.com
17,564 CGON shares proposed for sale (CGON) — prior 1,964 sold under 10b5-1 - Stock Titan
CG Oncology stock reaches all-time high at 72.0 USD - Investing.com
CG Oncology (NASDAQ:CGON) Trading Up 10.1% on Analyst Upgrade - MarketBeat
Why CG Oncology Stock Is Quietly Climbing Higher - TipRanks
CG Oncology (NASDAQ:CGON) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says - MarketBeat
CG Oncology Price Target Raised to $91.00/Share From $65.00 by JP Morgan - Moomoo
Massachusetts Financial Services Co. MA Trims Stock Position in CG Oncology, Inc. $CGON - MarketBeat
CG Oncology | 4: Statement of changes in beneficial ownership of securities-Officer DETORE JAMES M. - Moomoo
CG Oncology | 4: Statement of changes in beneficial ownership of securities-Officer Patterson Joshua F. - Moomoo
CG Oncology | 4: Statement of changes in beneficial ownership of securities-Officer Bellete Ambaw - Moomoo
COO Bellete Ambaw receives 107,508 CGON stock options in new grant - Stock Titan
CG Oncology (NASDAQ: CGON) CMO receives 79,216 stock options at $67.68 strike - Stock Titan
Officer at CG Oncology (CGON) awarded 45,266 stock options - Stock Titan
Cg Oncology Inc Stock (CGON) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):